metaEvidence - overview

button bars forest bayes pooled summary circles


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus placebo plus SoC
	sintillimab plus SoC vs. placebo plus SoC	1
versus Standard of Care (SoC)
	cemiplimab vs. Standard of Care (SoC)	1
	durvalumab alone vs. Standard of Care (SoC)	1
mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative
versus pemetrexed plus platin
	nivolumab plus SoC vs. pemetrexed plus platin	1
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3
	cemiplimab vs. Standard of Care (SoC)	1
	durvalumab alone vs. Standard of Care (SoC)	1
	nivolumab alone vs. Standard of Care (SoC)	2
	pembrolizumab alone vs. Standard of Care (SoC)	4
mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb
non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population
versus atezolizumab plus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel	1
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1
	atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	2
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1
versus pemetrexed plus platin
	atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin	1
	pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin	1
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1
squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1